Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3σ, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells

Anti-Cancer Drugs

Volumn 14, Issue 3, 2003, Pages 193-202

  Gagnon, Jacynthe ^a   Shaker, Sepideh ^a   Primeau, Mélanie ^a   Hurtubise, Annie ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

14 3 3 ; 5 aza 2 deoxycytydine; Breast cancer; Depsipeptide; DNA methylation; E cadherin; Histone deacetylation; TIMP3

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; FR 901228; PROTEIN 14 3 3; PROTEIN 14 3 3SIGMA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE G2 PHASE; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037358032     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200303000-00002     Document Type: Article

References (42)

1. Lawrence MM, Harold LA, Bonnie BA. Genes, chromatin, and breast cancer: an epigenetic tale [Review]. J Mammary Gland Biol Neoplasia 2001; 6:169-182.
2. Robertson KD, Jones PA. DNA methylation: past, present and future directions [Review]. Carcinogenesis 2000; 21:461-467.
3. Momparler RL, Bovenzi V. DNA methylation and cancer [Review]. J Cell Physiol 2000; 183:145-154.
4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joints genetics [Review]. Trends Genet 2000; 16:168-174.
5. Razin A, Riggs AD. DNA methylation and gene function. Science 1980; 210:604-610.
6. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, et al. Chronic myelogeneous leukemia in nonlymphoid blastic phase. Cancer 1999; 86:2632-2641.
7. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukemic activity of 5-AZA-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer 1991; 64:144-148.
8. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985; 30:277-286.
9. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs 1997; 8:358-368.
10. Wolffe AP. Histone deacetylase:a regulator of transcription. Science 1996', 272:371-372.
11. Archer SY, Hoddin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999; 9:171-174.
12. Nakajima h, Kim YB, Terano H, Yoshida M, Horinoushi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241:126-133.
13. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47:315-323.
14. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-728.
15. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001; 98:4990-4995.
16. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393:386-389.
17. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19:187-191.
18. Jones PA, Baylin SB. The fundamental ro4e of epigenetic events in cancer [Review]. Nat Genet 2002; 3:415-428.
19. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-107.
20. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001 Oct 1; 61:7025-7029.
21. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Volgelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616-620.
22. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97:6049-6054.
23. Takeichi M, Cadherin cells adhesion receptors as a morphogenetic regulator. Science 1991; 251:1451-5.
24. Graff JR, Herman JG, Lapidus RL, Chopra H, Xu R, Jarrard DF, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55:5195-5199.
25. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Davidson NE, Graff JR. Aberrant methylation of the estrogen receptor and E-cadherin 5′CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000; 15:4346-4348.
26. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89:1260-1270.
27. Andreu T, Beckers T, Thoenes E, Hilgard P, von Melchner H. Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (timp3) and collagen type I β2 (colla2) are epidermal growth factor-regulated growth repressers. J Biol Chem 1998; 273:13848-13854.
28. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59:798-802.
29. Bovenzi V, Momparler RL. Antineoplastic action of 5-aza-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001; 48:71-76.
30. Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-Aza-2′-deoxycytidine and histone deacetylatase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 2003; 103:177-184.
31. Valeriote F, Lin H. Synergistic interaction of anticancer drugs. Cancer Chemother Rep 1975; 59:895-899.
32. Momparler RL. In vitro systems for the evaluation of combination chemotherapy. Pharmacol Ther 1980; 8:21-25.
33. Sirchia SM, Ferguson AT, Sironi E, Subramayan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatln state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000; 19:1556-1563.
34. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-149.
35. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp Cell Res 1998; 241:126-133.
36. Beausejour CM, Eliopoulos N, Momparler L, Le NL, Momparler RL. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther 2001; 8:669-676.
37. Beausejour CM, Gagnon J, Primeau M, Momparler RL. Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 2002; 293:1478-1484.
38. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methyaltion for therapy of advanced non-small cell lung cancer. Lung Cancer 2001; 34:S111-S115.
39. Graff JR, Gabrielson E, FujiiH, Baylin SB, Herman JG. Methylation pattern of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogenous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 275:2727-2732.
40. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, et al. Transcriptional activation of estrogen receptor-α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000; 60:6890-6894.
41. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001; 24:151-161.
42. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 2001; 71:295-301.